2026-01-29 - Analysis Report
**Company Overview:**
Merck is a multinational pharmaceutical company that discovers, develops, manufactures, and markets a wide range of pharmaceuticals, vaccines, and animal health products.

**Return Rate Comparison:**
The cumulative return of Mrk (Merck) is 69.98%, compared to the cumulative return of S&P 500 (VOO) at 128.51%. The degree of divergence is -58.50, indicating a significant divergence.

**Historical Analysis (2016-2025):**
| Year    | CAGR | MDD  | Alpha | Beta | Cap(B) |
|---------|------|------|-------|------|-------|
| 2016-2018| 33.0% | 15.3% | 25.0% | 0.7  | 180.3B |
| 2017-2019| 39.0% | 15.3% | 14.0% | 0.7  | 214.6B |
| 2018-2020| 29.0% | 24.7% | 5.0%  | 0.7  | 193.0B |
| 2019-2021| -1.0% | 24.7% | -65.0%| 0.6  | 189.5B |
| 2020-2022| 41.0% | 22.9% | 36.0% | 0.5  | 274.4B |
| 2021-2023| 49.0% | 19.2% | 31.0% | 0.3  | 269.6B |
| 2022-2024| 18.0% | 25.3% | -11.0%| 0.3  | 246.0B |
| 2023-2025| -11.0%| 40.0% | -87.0%| 0.3  | 260.3B |

**Recent Stock Price Fluctuations:**
| Metric     | Value   |
|------------|---------|
| Close      | $107.92 |
| 5-day SMA  | $108.76 |
| 20-day SMA | $108.62 |
| 60-day SMA | $100.60 |
| Last-market | $106.85 |

**Market Risk Indicator (MRI) and Other Indicators:**
| Indicator | Value    |
|-----------|----------|
| MRI (0.9-1.0: High Investment, 0.7-0.9: Medium Investment, 0.4-0.7: Low Investment, <0.4: Very Risky) | 0.70    |
| RSI          | 47.18    |
| PPO          | -0.62    |
| Hybrid Signal| Buy (Cash 0%) |
| Risk Level    | Medium (MRI 0.70) |
| Expected Return | -3.60% |

**News and Significant Events:**
Several significant events have occurred recently, including:

* What's Fueling The Rally In Merck Stock? (Forbes)
* Why Merck Stock Jumped 40%? (Trefis)
* Merck veteran-led Eikon seeks U.S. IPO â€ (EIKN:Pending) (Seeking Alpha)
* Is Merck Stock a Value Trap in 2026 After 10% Returns Last Year? (TIKR.com)
* $MRK stock is down 3% today. Here's what we see in our data. (Quiver Quantitative)
* Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet (Finviz)

**Analyst Opinions:**
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): $117.48 / $135.00 / $86.00
```

**Recent Earnings Analysis:**
| Date     | EPS | Revenue |
|----------|-----|---------|
| 2025-11-05 | $2.32 | $17.28B |
| 2025-08-05 | $1.76 | $15.81B |
| 2025-05-02 | $2.01 | $15.53B |
| 2024-11-06 | $1.25 | $16.66B |
| 2025-11-05 | $1.25 | $16.66B |

**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

**Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Comprehensive Analysis Summary:**
Merck (MRK) has a cumulative return of 69.98%, significantly lower than the S&P 500 (VOO) at 128.51%. The company's historical analysis shows mixed results, with some periods of high growth and others of decline. The recent stock price fluctuations are relatively stable, with a 5-day SMA of $108.76 and a 20-day SMA of $108.62. The Market Risk Indicator (MRI) is 0.70, indicating a medium-risk investment. The RSI and PPO indicators are 47.18 and -0.62, respectively, indicating a sell signal. The Expected Return is -3.60%. Recent news and significant events suggest a rally in Merck stock, driven by factors such as a strong earnings report and a veteran-led IPO. Analyst opinions are overwhelmingly bullish, with a mean rating of 1.90 and a target price of $117.48. The company's revenue and profitability metrics show steady growth, with a revenue of $17.28B and a profit margin of 77.69% in the latest quarter.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.